Biochemical and Biophysical Research Communications
Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways
Section snippets
Methods
Animals. The bone marrows of 5- to 6-week-old C57BL/6 (I-Ab haplotype) mice were used to generate hematopoietic progenitor cells. Id1−/− mutant mice (C57BL6/SV129, also of I-Ab haplotype), a kind gift from Dr. Robert Benezra (Memorial Sloan-Kettering Cancer Center, NY), were bred and raised at the Beth Israel Deaconess Medical Center (Boston, MA) animal facility and also used for bone marrow isolation.
Cell lines and antibodies. The Ova-specific (residues 323–339) T-cell hybridoma B097.1, a CD4+
Acknowledgments
We sincerely thank Dr. Robert Benezra for his generous gift of the Id knockout mice. This work was partly supported by NIH grants CA78383, HL072178, and HL70567 and also a grant from American Cancer Society to D.M.; PO1 AI50157 to D.M.B. S.W.R. was supported by a Fellowship award from the National Kidney Foundation of Massachusetts.
References (21)
- et al.
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
Blood
(1998) - et al.
Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts
Cell. Immunol.
(1996) - et al.
Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors
Cell. Immunol.
(1996) - et al.
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor
Blood
(1998) - et al.
Angiogenesis and metastasis
Eur. J. Cancer
(1996) - et al.
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
Clin. Cancer Res.
(1999) - et al.
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
J. Immunol.
(1998) - et al.
Immunobiology of dendritic cells
Ann. Rev. Immunol.
(2000) - et al.
Dendritic cell lineage, plasticity and cross-regulation
Nat. Immunol.
(2001) - et al.
Dendritic cells in cancer immunotherapy
Ann. Rev. Immunol.
(2000)
Cited by (87)
Chondroitin sulfate-based prodrug nanoparticles enhance photodynamic immunotherapy via Golgi apparatus targeting
2022, Acta BiomaterialiaCitation Excerpt :PDT-treated tumor cells secret high levels of numerous pro-inflammatory cytokines, such as interleukin 10 (IL-10) or transforming growth factor (TGF-β), which inhibit T cells [16]. PDT can also increase the levels of the vascular endothelial growth factor (VEGF), which blocks DCS maturation, leading to the formation of immature DCs (iDCs) [17,18]. Blockade of the immunosuppressive cytokines IL-10, TGF-β, and VEGF improves the ability to PDT to treat tumors [19], suggesting that the combination of PDT with inhibitors [20], such as antagonistic antibodies [21], small molecules, cytokine traps, or small interfering RNAs (siRNAs) [22], may improve treatment efficacy.
Dendritic cell vaccine therapy for colorectal cancer
2021, Pharmacological ResearchCitation Excerpt :Lastly, tumor-derived blood vessels may serve to inhibit the collective effects of DC vaccines. Sustained tumor-produced VEGF can mediate detrimental effects to DC function through mechanisms that include inducing PD-L1 expression on myeloid DCs, impairing mature DC mobility, and suppressing expression of MHC class II and other costimulatory molecules [146–150]. Although anti-angiogenic agents such as VEGF-specific antibodies (e.g., bevacizumab) and small molecule drugs (e.g., axitinib, dasatinib, sunitinib) have been approved for some time, resistance to these monotherapies develops quickly in patients due to tumor blood vessels adopting compensatory reliance on other growth factors [151].
Recent advances in light-triggered cancer immunotherapy
2024, Journal of Materials Chemistry BDendritic cell subsets in cancer immunity and tumor antigen sensing
2023, Cellular and Molecular Immunology